跳至主要内容
临床试验/NCT01232361
NCT01232361已完成不适用

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

International Maternal Pediatric Adolescent AIDS Clinical Trials Group22 个研究点 分布在 2 个国家目标入组 127 人开始时间: 2010年10月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
127
试验地点
22
主要终点
Estimation of steady-state oral clearance (Cl/F) for each psychiatric study medication is the primary outcome.

研究概览

简要总结

The main purpose of this study is to find out how stimulant medications (methylphenidate or amphetamine/ dextroamphetamine) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)are processed in HIV-1 infected and HIV-uninfected children and adolescents.

详细描述

P1080 is a pilot population pharmacokinetic study of HIV-1 infected and uninfected children and adolescents who are taking methylphenidate or amphetamine/ dextroamphetamine for the treatment of ADHD. Prescribing various psychiatric medications in combination with antiretroviral regimens is a standard clinical practice occurring without adequate evidence regarding benefits and risks. The goals of this study are to determine plasma concentrations of psychiatric and antiretroviral medications in children and adolescents. Psychiatric medication dose requirement and exposure in HIV-1 infected subjects will be compared to that seen in uninfected children and adolescents, and antiretroviral exposure will be compared to published studies in children and adolescents.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
6 Years 至 25 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Estimation of steady-state oral clearance (Cl/F) for each psychiatric study medication is the primary outcome.

时间窗: duration of study

Additional pharmacokinetic parameters \[area under the concentration-time curve (AUC), apparent volume of distribution (Vd/F), half-life (t½), pre-dose concentration (Cpre), maximum concentration (Cmax), corresponding time of maximum concentration (Tmax), elimination rate constant (ke), and between and within-subject variability\] for the selected psychiatric medications in HIV-1 infected and uninfected children and adolescents will also be determined.

次要结局

未报告次要终点

研究者

发起方
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
申办方类型
Network
责任方
Sponsor

研究点 (22)

Loading locations...

相似试验